Ivermectin for Covid-19

Discussion of scholarly papers published on Ivermectin, starting from the article of Caly et al. in Antiviral Research, available online April 3, 2020, and of some news that we can find about the use of this drug for the treatment of Covid-19. A list of clinical trials is also given. The proposed discussion was made in a series of versions from 14 June this of 28 July 2020.  For what concerns scholarly papers, we report among them a preprint posted on 10 June in MedRχiv,  which concludes that Ivermectin was associated with lower mortality during treatment of Covid-19.  We report also the preprint, posted on 8 July in MedRχiv too, showing the result of a clinical trial. This preprint tells, in its conclusions that add-on use of Ivermectin is giving better results when compared to controls, in particular a significant shorter hospitalization. Among news, we consider especially the news regarding the use of Ivermectin in Peru. The case of Iquitos is discussed in detail. In Iquitos, capital of the Department of Loreto, by May 25 Covid-19 cases and deaths had dropped notably, as reported on the web. Epidemic data in this region are considered. Recent news (July 27), displaying the observation of  rare symptoms of Covid-19, is also reported in detail. The observation was related to a set of more than 3,000 patients in Lima. The formulation of Ivermectin used in Peru is also discussed, in particular that of the oral solution, disclosed by the Peruvian Government.